[
  {
    "ts": null,
    "headline": "Q2 Earnings Roundup: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Segment",
    "summary": "The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q2, starting with Viatris (NASDAQ:VTRS).",
    "url": "https://finnhub.io/api/news?id=343cce78a95b10e9f73cb3ab61df5d332253d7cf870c4ec27f41d3f76afe6238",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755660862,
      "headline": "Q2 Earnings Roundup: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Segment",
      "id": 136438115,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q2, starting with Viatris (NASDAQ:VTRS).",
      "url": "https://finnhub.io/api/news?id=343cce78a95b10e9f73cb3ab61df5d332253d7cf870c4ec27f41d3f76afe6238"
    }
  }
]